Antiemetics in children receiving cancer chemotherapy: a double-blind prospective randomized study comparing metoclopramide with chlorpromazine

This is the first prospective randomized study comparing commonly used antiemetics in children receiving cancer chemotherapy. We compared metoclopramide (MCP) with chlorpromazine (CLP), both administered in conventional doses, in 50 cancer patients aged 6 to 18 years who were receiving emetic chemot...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 4; no. 7; p. 1110
Main Authors Graham-Pole, J, Weare, J, Engel, S, Gardner, R, Mehta, P, Gross, S
Format Journal Article
LanguageEnglish
Published United States 01.07.1986
Subjects
Adolescent
Antiemetics
Antineoplastic Agents - adverse effects
Child
Chlorpromazine - therapeutic use
Clinical Trials as Topic
Female
Humans
Male
Metoclopramide - therapeutic use
Prospective Studies
Random Allocation
Online AccessGet more information

Cover

More Information
Summary:This is the first prospective randomized study comparing commonly used antiemetics in children receiving cancer chemotherapy. We compared metoclopramide (MCP) with chlorpromazine (CLP), both administered in conventional doses, in 50 cancer patients aged 6 to 18 years who were receiving emetic chemotherapy. CLP proved significantly better than MCP in reducing both the frequency of vomiting (P less than .05) and the duration of nausea and vomiting (P less than .025). Extrapyramidal reactions (EPRs) were more common in MCP-treated patients. We conclude that, in the standard doses used, CLP is a better overall antiemetic than MCP for children receiving intensive chemotherapy. However, further prospective pediatric studies of antiemetic combinations are needed.
ISSN:0732-183X
1527-7755
DOI:10.1200/JCO.1986.4.7.1110